Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

NCT03449446 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

395

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonalcoholic Steatohepatitis

Interventions

DRUG: SEL
DRUG: FIR
DRUG: CILO
DRUG: Placebo to match FIR
DRUG: Placebo to match CILO
DRUG: Placebo to match SEL

Sponsor

Gilead Sciences